Developer docs
API playgroundTry for free, no card

Search company profiles

APIM Therapeutics

Full company profile

uuid0004n47

Namestring
APIM Therapeutics
Legal namestring
APIM Therapeutics AS
Company typeenum
Private
Founded yearint
2010
Descriptiontext

APIM Therapeutics AS is a venture-capital financed Norwegian biotech company founded in 2009/2010 as a spin-off from the Norwegian University of Science and Technology (NTNU) in Trondheim. The company is developing proprietary peptide drugs that target PCNA (Proliferating Cell Nuclear Antigen) and the novel APIM (PCNA-interacting motif) interaction, a therapeutic intervention point critical in regulating cellular stress responses and tumor evasion from therapy. Its lead drug candidate, ATX-101, is a first-in-class cell-penetrating peptide that rapidly penetrates cells and impairs PCNA/APIM-containing protein complexes, thereby modulating DNA repair, signaling pathways (MAPK/AKT/ERBB2/EGFR), and apoptotic response in cancer cells.

ATX-101 has completed a Phase I first-in-human clinical study demonstrating favorable safety profile and disease stabilization in advanced progressive tumor patients, with a Phase Ib study in platinum-sensitive ovarian cancer concluded and a Phase II investigator-initiated study in lipo- and leiomyosarcoma ongoing at Columbia University Irving Medical Center. The company holds no commercial revenue and operates with 1-10 employees, supported by more than EUR 25M in cumulative funding from public and private Norwegian sources including Sarsia Seed, Trond Mohn Stiftelse, Investinor AS, and UNIFOB. Revenue generation is anticipated through future partnering deals, licensing agreements, or eventual product commercialization.

The company's business model is a clinical-stage biotech go-to-market pursued through research collaborations, partnering opportunities with pharmaceutical companies, and active participation in industry conferences (Swiss Biotech Day, BioEurope, ASCO, ESMO). Its core customer segment is oncology patients with advanced cancers lacking standard treatment options, including ovarian cancer, sarcoma, glioblastoma, multiple myeloma, and bladder cancer. The proposed all-stock merger with Nordic Nanovector ASA announced in November 2022 was cancelled in December 2022 due to insufficient shareholder approval, leaving APIM Therapeutics operating independently and advancing its clinical pipeline.

Short descriptiontext

APIM Therapeutics AS is a Norwegian clinical-stage biotech developing ATX-101, a first-in-class cell-penetrating peptide targeting PCNA/APIM interactions for cancer treatment, with Phase Ib/II trials in ovarian cancer and sarcoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrekstad, Norway
HQ citystring
Brekstad
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, cancer drug development, PCNA targeting, oncology clinical trials, biotech research
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development & Clinical Trials
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company developing ATX-101 through clinical trials. Revenue generation anticipated through partnering deals, licensing agreements, or eventual product commercialization.

apimtherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

APIM Therapeutics is developing ATX-101, a first-in-class, clinical-stage cell-penetrating peptide drug candidate that targets the interaction between Proliferating Cell Nuclear Antigen (PCNA) and APIM-containing protein complexes in cancer cells. The lead candidate has been tested in ovarian cancer (Phase Ib) and sarcoma (Phase II) patients as both monotherapy and combination treatment, and is designed to potentiate DNA-damaging drugs, microtubule-targeting agents, molecular targeted agents, and radiotherapy while re-sensitizing resistant cancer cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I study demonstrated favorable safety profile with disease stabilization in advanced, progressive tumor patients lacking standard treatment options
+2 more records
Product overview1 text field

APIM Therapeutics is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. The company's lead product is ATX-101, a first-in-class cell-penetrating peptide that targets proliferating cell nuclear antigen (PCNA). ATX-101 has completed Phase I clinical studies demonstrating favorable safety profile and disease stabilization, and is currently undergoing Phase Ib testing in ovarian cancer and Phase II testing in sarcoma as both monotherapy and combination treatment.

Product and service1 record
1ATX-101
CategoryClinical-stage oncology peptide drug
Description

First-in-class, clinical-stage cell-penetrating peptide drug candidate comprising the APIM motif together with cell penetration and nuclear localization domains. It targets PCNA/APIM-containing protein complexes, is being tested in ovarian cancer (Phase Ib) and sarcoma (Phase II) patients, and potentiates the action of DNA-damaging drugs, microtubule-targeting agents, molecular targeted agents, and radiotherapy. Intended ultimately for oncology pharmaceutical partners and cancer patients with advanced, treatment-resistant disease.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Investigator-initiated Phase II clinical study in sarcoma (lipo- and leiomyosarcoma) conducted by Columbia University. APIM supports this clinical trial as an important proof-of-concept study for ATX-101. Preliminary data confirmed therapeutic potential.

2Nordic Nanovector ASA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

In November 2022, APIM Therapeutics and Nordic Nanovector announced a definitive merger agreement to combine in an all-stock transaction. The merger was cancelled in December 2022 as it did not obtain sufficient shareholder votes at Nordic Nanovector's Extraordinary General Meeting.

apimtherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

APIM Therapeutics is a biotech spin-off from NTNU (Trondheim). The company's technology originated from research at NTNU, and the CSO (Marit Otterlei) is an NTNU Professor. Ongoing research collaboration and scientific advisory relationship.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

APIM Therapeutics

Oncology Therapeuticsapimtherapeutics.com

APIM Therapeutics AS is a Norwegian clinical-stage biotech developing ATX-101, a first-in-class cell-penetrating peptide targeting PCNA/APIM interactions for cancer treatment, with Phase Ib/II trials in ovarian cancer and sarcoma.

What APIM Therapeutics does

APIM Therapeutics AS is a venture-capital financed Norwegian biotech company founded in 2009/2010 as a spin-off from the Norwegian University of Science and Technology (NTNU) in Trondheim. The company is developing proprietary peptide drugs that target PCNA (Proliferating Cell Nuclear Antigen) and the novel APIM (PCNA-interacting motif) interaction, a therapeutic intervention point critical in regulating cellular stress responses and tumor evasion from therapy. Its lead drug candidate, ATX-101, is a first-in-class cell-penetrating peptide that rapidly penetrates cells and impairs PCNA/APIM-containing protein complexes, thereby modulating DNA repair, signaling pathways (MAPK/AKT/ERBB2/EGFR), and apoptotic response in cancer cells.

ATX-101 has completed a Phase I first-in-human clinical study demonstrating favorable safety profile and disease stabilization in advanced progressive tumor patients, with a Phase Ib study in platinum-sensitive ovarian cancer concluded and a Phase II investigator-initiated study in lipo- and leiomyosarcoma ongoing at Columbia University Irving Medical Center. The company holds no commercial revenue and operates with 1-10 employees, supported by more than EUR 25M in cumulative funding from public and private Norwegian sources including Sarsia Seed, Trond Mohn Stiftelse, Investinor AS, and UNIFOB. Revenue generation is anticipated through future partnering deals, licensing agreements, or eventual product commercialization.

The company's business model is a clinical-stage biotech go-to-market pursued through research collaborations, partnering opportunities with pharmaceutical companies, and active participation in industry conferences (Swiss Biotech Day, BioEurope, ASCO, ESMO). Its core customer segment is oncology patients with advanced cancers lacking standard treatment options, including ovarian cancer, sarcoma, glioblastoma, multiple myeloma, and bladder cancer. The proposed all-stock merger with Nordic Nanovector ASA announced in November 2022 was cancelled in December 2022 due to insufficient shareholder approval, leaving APIM Therapeutics operating independently and advancing its clinical pipeline.

APIM Therapeutics firmographics

Firmographics
Name
APIM Therapeutics
Legal name
APIM Therapeutics AS
Website
https://apimtherapeutics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
APIM Therapeutics AS is a Norwegian clinical-stage biotech developing ATX-101, a first-in-class cell-penetrating peptide targeting PCNA/APIM interactions for cancer treatment, with Phase Ib/II trials in ovarian cancer and sarcoma.
Ownership category
akta.pro rank

Where APIM Therapeutics is headquartered

Location

Headquarters

HQ city
Brekstad
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

APIM Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pipeline Development & Clinical Trials: Pre-revenue clinical-stage biotech company developing ATX-101 through clinical trials. Revenue generation anticipated through partnering deals, licensing agreements, or eventual product commercialization.

Go-to-market motion1 record

Marketing channels3 records

APIM Therapeutics product offering

Product offering

Core offering

APIM Therapeutics is developing ATX-101, a first-in-class, clinical-stage cell-penetrating peptide drug candidate that targets the interaction between Proliferating Cell Nuclear Antigen (PCNA) and APIM-containing protein complexes in cancer cells. The lead candidate has been tested in ovarian cancer (Phase Ib) and sarcoma (Phase II) patients as both monotherapy and combination treatment, and is designed to potentiate DNA-damaging drugs, microtubule-targeting agents, molecular targeted agents, and radiotherapy while re-sensitizing resistant cancer cells.

Product overview

APIM Therapeutics is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. The company's lead product is ATX-101, a first-in-class cell-penetrating peptide that targets proliferating cell nuclear antigen (PCNA). ATX-101 has completed Phase I clinical studies demonstrating favorable safety profile and disease stabilization, and is currently undergoing Phase Ib testing in ovarian cancer and Phase II testing in sarcoma as both monotherapy and combination treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATX-101 First-in-class, clinical-stage cell-penetrating peptide drug candidate comprising the APIM motif together with cell penetration and nuclear localization domains. It targets PCNA/APIM-containing protein complexes, is being tested in ovarian cancer (Phase Ib) and sarcoma (Phase II) patients, and potentiates the action of DNA-damaging drugs, microtubule-targeting agents, molecular targeted agents, and radiotherapy. Intended ultimately for oncology pharmaceutical partners and cancer patients with advanced, treatment-resistant disease.

Quantifiable outcome

  • Phase I study demonstrated favorable safety profile with disease stabilization in advanced, progressive tumor patients lacking standard treatment options
  • +2 more outcomes

Companies that use APIM Therapeutics

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

APIM Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

APIM Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Columbia University Irving Medical CentercoreStrategic or Co-development PartnerInvestigator-initiated Phase II clinical study in sarcoma (lipo- and leiomyosarcoma) conducted by Columbia University. APIM supports this clinical trial as an important proof-of-concept study for ATX-101. Preliminary data confirmed therapeutic potential.
  • Nordic Nanovector ASAminorStrategic or Co-development PartnerIn November 2022, APIM Therapeutics and Nordic Nanovector announced a definitive merger agreement to combine in an all-stock transaction. The merger was cancelled in December 2022 as it did not obtain sufficient shareholder votes at Nordic Nanovector's Extraordinary General Meeting.
  • Norwegian University of Science and Technology (NTNU)coreStrategic or Co-development PartnerAPIM Therapeutics is a biotech spin-off from NTNU (Trondheim). The company's technology originated from research at NTNU, and the CSO (Marit Otterlei) is an NTNU Professor. Ongoing research collaboration and scientific advisory relationship.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

APIM Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

APIM Therapeutics social profiles

Digital presence

APIM Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

APIM Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

APIM Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

APIM Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APIM Therapeutics

What does APIM Therapeutics do?

APIM Therapeutics is developing ATX-101, a first-in-class, clinical-stage cell-penetrating peptide drug candidate that targets the interaction between Proliferating Cell Nuclear Antigen (PCNA) and APIM-containing protein complexes in cancer cells. The lead candidate has been tested in ovarian cancer (Phase Ib) and sarcoma (Phase II) patients as both monotherapy and combination treatment, and is designed to potentiate DNA-damaging drugs, microtubule-targeting agents, molecular targeted agents, and radiotherapy while re-sensitizing resistant cancer cells.

Is APIM Therapeutics a public or private company?

APIM Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was APIM Therapeutics founded?

APIM Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is APIM Therapeutics based?

APIM Therapeutics is headquartered in Brekstad, Norway, in the Europe region.

How does APIM Therapeutics make money?

One revenue line is on record: pipeline Development & Clinical Trials.

Does APIM Therapeutics have an API?

No public API is recorded for APIM Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNordic Nanovector ASA Results for the Second Half and Full Year 2022Nordic Nanovector ASA reported its second half and full year 2022 results, disclosing the discontinuation of its PARADIGME global Phase 2b trial of Betalutin® for 3rd-line follicular lymphoma after the drug profile failed to meet study success thresholds (ORR 31.1% vs. required 40%; CRR 14.8% vs. required 25%). The company has undergone severe restructuring, cutting staff from 40 to 6 employees and reducing operating expenses, while its proposed merger with APIM Therapeutics was rejected by shareholders at an Extraordinary General Meeting on 1 December 2022. The new board has appointed Carnegie Investment Bank to explore strategic options, with current cash resources expected to fund operations into Q2 2024.PR NewswireNordic Nanovector ASA Results for the Second Half and Full Year 2022Nordic Nanovector ASA reported its 2022 full-year results, disclosing the discontinuation of its PARADIGME Phase 2b trial of Betalutin® for third-line follicular lymphoma after the treatment showed insufficient efficacy (31.1% ORR vs 40% threshold, 14.8% CRR vs 25% threshold). The company implemented a major restructuring including staff reduction from 40 to 6 employees and board changes following shareholder rejection of a proposed merger with APIM Therapeutics at an Extraordinary General Meeting on 1 December 2022. The new board has appointed Carnegie Investment Bank to explore strategic options and expects current cash reserves of approximately NOK 60 million to fund operations into Q2 2024.PR NewswireNordic Nanovector update following shareholder vote against proposed merger with APIM TherapeuticsNordic Nanovector ASA announced that shareholders voted down the proposed merger with APIM Therapeutics AS at an Extraordinary General Meeting on 1 December 2022, as it failed to obtain sufficient majority support. Following this outcome, the current Board of Directors has resigned and will not stand for re-election at a new EGM, while interim CEO and CFO Malene Brondberg will also exit the company. North Energy, Nordic Nanovector's largest shareholder, will propose the agenda for the new EGM where new board members and a new CEO search will be addressed.PR NewswireNordic Nanovector update following shareholder vote against proposed merger with APIM TherapeuticsNordic Nanovector ASA announced that its proposed merger with APIM Therapeutics AS was voted down at an Extraordinary General Meeting on 1 December 2022 after failing to obtain sufficient shareholder support. Following this outcome, the current Board of Directors has decided to resign and not stand for re-election, and interim CEO/CFO Malene Brondberg will also exit the company. North Energy, the largest shareholder, will convene a new EGM to elect a new board and nomination committee, after which a search for a permanent CEO will commence.PR NewswireNordic Nanovector ASA: Extraordinary General Meeting heldNordic Nanovector ASA held an Extraordinary General Meeting on 1 December 2022 in Oslo, Norway. The proposed transaction with APIM Therapeutics AS failed to obtain sufficient shareholder votes and was voted down. As a consequence, the EGM did not proceed to vote on the remaining agenda items.PR NewswireNordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM TherapeuticsNordic Nanovector ASA has launched a dedicated Norwegian-language section on its website providing shareholders with information about its proposed merger with APIM Therapeutics, following a webcast on 24 November 2022 where company leadership presented merger details and answered shareholder questions. After evaluating 25 potential merger and acquisition opportunities, the Board determined that the merger represents the best option given the significant potential of ATX-101, a novel anti-cancer peptide currently in Phase 2 trials, and expects the combined company to leverage shared development expertise to generate additional drug candidates. The merger is backed by both companies' Boards of Directors and has received support from Folketrygdfondet, Nordic Nanovector's largest shareholder, with a shareholder vote scheduled for 29 November 2022.PR NewswireNordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM TherapeuticsNordic Nanovector ASA has launched a dedicated Norwegian-language section on its website with information for shareholders regarding the proposed merger with APIM Therapeutics, including a recorded webcast from November 24, 2022. After evaluating 25 merger and acquisition opportunities, the company determined the merger with APIM represents the best option, driven by the significant potential of ATX-101, a novel anti-cancer peptide currently in Phase 2 trials. Both companies' boards of directors have endorsed the merger, which is also supported by Nordic Nanovector's largest shareholder Folketrygdfondet, with a shareholder vote scheduled for November 29, 2022.PR NewswireNordic Nanovector: Invitation to webcast regarding proposed merger with APIM TherapeuticsNordic Nanovector ASA announced it will host a webcast on November 24, 2022, to present and discuss the proposed merger with APIM Therapeutics. Executives from both companies, including Nordic Nanovector's Chairman and Interim CEO and APIM Therapeutics' CEO, will participate in the presentation and Q&A session. The webcast is being held in English with a Norwegian Q&A option, and registration details were provided for investors and stakeholders.PR NewswireNordic Nanovector: Invitation to webcast regarding proposed merger with APIM TherapeuticsNordic Nanovector is hosting a webcast to discuss its proposed merger with APIM Therapeutics, following a stock exchange announcement made on November 21. The event will feature presentations and a Q&A session by the leadership of both companies. This communication serves to provide investors with details regarding the strategic combination of the two entities.